NCT04610866: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat

Sponsor: National Heart, Lung, and Blood Institute (NHLBI). Phase: PHASE1. Conditions: Sickle Cell Disease, Hemolytic Anemia